hotspot -WSS

hotspot

author：comprehensive 2025-09-06 04:17:21 - browse：4

Verve Therapeutics said Sunday that the first 10 people to receive a one-time treatment powered by a form of CRISPR called base editing showed reductions in bad cholesterol levels — study results that are preliminary but signal the potential for gene-editing treatments to benefit people with an inherited type of cardiovascular disease.

Three of the study participants treated with potentially therapeutic doses of the Verve drug, called VERVE-101, showed reductions in LDL-C levels of 39%, 48%, and 55%, respectively. The latter patient’s decline in so-called “bad” cholesterol was maintained for six months.

The Verve-101 study results were presented at the American Heart Association conference and are the first data in patients from a therapy that uses base editing to change individual letters of DNA. Verve licensed the base-editing technology from Beam Therapeutics.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： AI models in health care face new federal disclosure requirements

focus

WSS

STAT Health News: mRNA flu shots, Purdue SCOTUS case, etc

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

Pediatric cancer treatments threatened by a new FDA policy

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

How to pay for weight loss drugs and save Medicare

knowledge

hotspot

focus

What does generative AI mean for health care? We asked experts

Pregnancy discrimination could be enabled by AI

As demand for Covid shots wanes, Moderna seeks its next success

Teach medical students about patients with intellectual disabilities

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Why sickle cell disease is getting the first CRISPR treatment

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Congenital heart disease patients face new threat of heart failure

Bright Health sells Medicare Advantage business to Molina

Organ aging and disease risk measured by new blood test

hotspot

In diabetes hearing, Sanders takes on a new foe: food makers

Diagnostic tests are hitting their mathematical limits

J&J to emphasize cancer drugs, stop much of its vaccine research

Why sickle cell disease is getting the first CRISPR treatment

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

U.K. Biobank has 500,000 peoples' genome sequences available

entertainment

knowledge

focus

hotspot